Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

Chun Loo Gan,J. Connor Wells,andrew schmidt,Thomas Powles,Ben Tran,Luis Meza,Chris Labaki,Jae-Lyun Lee,Lori Wood,J Shapiro,D. Scott Ernst,Anil Kapoor,Christina Canil,Takeshi Yuasa,Rana R. McKay,Benoit Beuselinck,Frede Donskov,Shaan Dudani,Toni K. Choueiri,Daniel Yick Chin Heng

Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

2021

4554Background: IPI NIVO is approved for 1L treatment of IMDC intermediate/poor risk mRCC based on the CHECKMATE 214 trial. Herein, we report the clinical effectiveness of 1L IPI NIVO and second li...

Keywords:

Nivolumab
Internal medicine
clinical effectiveness
first line
Medicine
Ipilimumab
poor risk
Renal cell carcinoma
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations